Global private equity and venture capital news and research

French biopharma InnaVirVax closes €3.7m Series B

14 Feb 2012

InnaVirVax, a French biopharmaceutical company that develops therapies for AIDS and HIV infection, has closed a €3.7m Series B financing round led by Pradeyrol Développement and private equity firms Fa Dièse and Fonds Régional de Co-Investissement Ile-de-France (FRCI).

InnaVirVax is dedicated to the development of therapeutic and diagnostic solutions in pathologies associated with immune dysregulation.

The funding will primarily enable the company to conduct phase I/IIa clinical trials of VAC-3S immunotherapy, it said.

Exising investors CapDecisif 2 and G1J Ile-de-France also participated in the round.

Copyright © 2012 AltAssets


AltAssets Mobile App

To access the latest private equity news and stories download the new AltAssets mobile app from the

Leave a Reply

You must be logged in to post a comment.

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2016